SCHEMBL16235652

SCHEMBL16235652

COC(=O)c1cccc(S(=O)(=O)Nc2cncc(Cl)c2O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 1/20 0.55
▸ ACLY P53396 4/20 0.52
▸ KDM4E B2RXH2 4/20 0.49
▸ TSHR P16473 2/20 0.49
▸ PTK2B Q14289 1/20 0.49
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ TCF4 P15884 2/20 0.46
▸ CTNNB1 P35222 2/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ HSPD1 P10809 1/20 0.45
▸ PTPN2 P17706 1/20 0.45
▸ PTPN1 P18031 1/20 0.45
▸ PTPN5 P54829 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16235471 0.87 KDM4E (0.65) ACLYKDM4ETSHRPTK2BKMT2A
SCHEMBL16235275 0.83 HSD11B1 (0.47) KDM4ETSHRPTK2BSMN1; SMN2LMNA
SCHEMBL16235212 0.80 SLC40A1 (0.58) SLC40A1ACLYKDM4ETSHRPTK2B
SCHEMBL12406979 0.79 KDM4E (0.60) SLC40A1ACLYKDM4ETSHRPTK2B
SCHEMBL16235161 0.78 ALDH1A1 (0.54) ACLYLMNAKMT2AMEN1RAB9A
SCHEMBL16235055 0.76 ALDH1A1 (0.47) TSHRLMNAKMT2AMEN1PKM
SCHEMBL28053418 0.75 SLC40A1 (0.56) SLC40A1BRD4KMT2AMEN1HSD17B10
SCHEMBL16234955 0.75 KMT2A (0.52) ACLYKDM4ELMNAKMT2AMEN1
SCHEMBL24298259 0.75 SLC40A1 (0.58) SLC40A1ACLYKDM4ETSHRPTK2B
SCHEMBL16235417 0.74 SLC40A1 (0.51) SLC40A1ACLYKDM4ETSHRPTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-11-13 — — US disclosed
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2018-06-07 — — US disclosed
US-9873687-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2018-01-23 — — US disclosed
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-04-28 — — US disclosed
CN-105377837-A N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors ACTIVE BIOTECH AB 2016-03-02 — — CN disclosed
EP-2925743-B1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2016-02-03 — — EP disclosed
EP-2925743-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2015-10-07 — — EP disclosed
WO-2014184234-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2014-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10125125-B2 N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors S100A9, S100B, S100A10 SLC40A1 370/4885ACLY 4724/4885KDM4E 3512/4885
US-20180155330-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100B, S100A10 SLC40A1 370/4885ACLY 4724/4885KDM4E 3512/4885
US-20160115158-A1 N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B SLC40A1 751/4885ACLY 4827/4885KDM4E 3670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback